Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients

Tacrolimus is an important immunosuppressant used in the treatment of myasthenia gravis (MG). However, the population pharmacokinetic (PK) characteristics together with the exposure‐response of tacrolimus in the treatment of MG remain largely unknown. In this study, we aimed to develop a population...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Di, Yao, Qingyu, Chen, Wenjun, Yin, Jian, Hou, Shifang, Tian, Xiaoxin, Zhao, Ming, Zhang, Hua, Yang, Liping, Zhou, Tianyan, Jin, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349186/
https://www.ncbi.nlm.nih.gov/pubmed/37060188
http://dx.doi.org/10.1002/psp4.12966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349186/
https://www.ncbi.nlm.nih.gov/pubmed/37060188
http://dx.doi.org/10.1002/psp4.12966

Ejemplares similares